Feasibility of Internet-based HIV Prevention Research
調査の概要
詳細な説明
In the past decade, injection drug use (IDU) has been linked to rural and urban HIV outbreaks, increased hepatitis C virus (HCV) transmission, and skyrocketing overdose rates in the US. Internet-based mail delivery public health programs mail naloxone or other HIV prevention supplies where allowed by law. Recruiting people who inject drugs (PWID) for research has traditionally been done in person, and the feasibility of collecting data from those who are recruited via the internet is unknown. Thus, the study's objectives are to: (1) recruit a representative sample of people who inject drugs for internet-based HIV prevention research; and (2) test the feasibility of at-home HIV testing for people who inject drugs.
This study will use social media to recruit 500 PWID. Investigators will assess the feasibility of online assessments and PWID's ability to perform at-home self-administered HIV testing. Participants will complete online questionnaires at baseline and investigators will mail participants HIV testing kits that they will self-administer and mail to a central laboratory. No other supplies will be mailed to participants.
- Recruitment will occur through with study advertisements on social media platforms and websites (i.e., Reddit, Twitter, Facebook, Instagram).
- Participants who click on an advertisement or study link will be taken to a screening questionnaire and informed consent page programmed into Qualtrics.
- To help minimize potentially fraudulent participants, the program will use cookies to block multiple submissions from a given device. Study staff will also manually review all surveys flagged for suspicious responses using a pre- determined process, such as comparing responses from the same Internet Protocol (IP) addresses, and examining those from proxy-IP addresses.
- Participants who complete informed consent and the baseline questionnaire will provide an e-mail address (to receive compensation) and a physical address where an HIV testing kit could be mailed.
- The research team will mail participants an OraSure HIV-1 Oral Specimen Collection Device. A self-addressed and stamped envelope will be included with the collection kit. Participants will follow enclosed directions to collect oral-fluid samples and mail them to the study laboratory for analysis. Envelopes and samples will only be marked with a bar code and not with any other personal identifiers (e.g., name or address).
- Research staff will follow a defined protocol to deliver any positive HIV tests results.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Guillermo Sanchez-Fat, MD
- 電話番号:347-514-1513
- メール:guillermo.sanchezfat@einsteinmed.edu
研究場所
-
-
New York
-
The Bronx、New York、アメリカ、10467
- 募集
- Montefiore Medical Center
-
主任研究者:
- Aaron Fox, MD
-
コンタクト:
- Guillermo Sanchez-Fat, MD
- 電話番号:347-514-1513
- メール:guillermo.sanchezfat@einsteinmed.edu
-
コンタクト:
- Aaron Fox, MD
- 電話番号:718-920-7173
- メール:adfox@montefiore.org
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- 18 years or older
- US residency
- English or Spanish fluency
- injection drug use (self-report, past 30 days)
- basic reading comprehension
Exclusion Criteria:
- HIV status known to be positive
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:At-home self-administered HIV testing
All participants will be mailed at-home self-administered HIV testing kits
|
Investigators will mail participants an OraSure HIV-1 Oral Specimen Collection Device.
The kit will include a self-addressed and stamped envelope with the collection device.
Participants will follow enclosed directions to collect oral-fluid samples and mail them to the study laboratory for analysis.
Envelopes and samples will only be marked with a bar code and not with any other personal identifiers (e.g., name or address).
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
HIV test completion
時間枠:12 months
|
This outcome will be the percentage of enrolled participants that have valid HIV testing results.
The numerator will be the number of HIV test kits collected properly and sent to the laboratory for testing successfully.
The denominator will be the total number of enrolled participants.
|
12 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Screening feasibility
時間枠:Baseline
|
This outcome will measure the percentage of potential participants who complete enrollment.
The numerator will be the number of participants that complete screening questionnaires and provide informed consent.
The denominator will be the total number of potential participants that click on study advertisement or link to the study.
|
Baseline
|
|
Feasibility of study procedures
時間枠:12 months
|
This outcome will be the percentage of enrolled participants that complete baseline questionnaires and mail in HIV testing kits to the laboratory.
The numerator will be the number of HIV test kits received at the laboratory and the denominator will be the total number of enrolled participants.
|
12 months
|
協力者と研究者
捜査官
- 主任研究者:Aaron Fox、Montefiore Medical Center/Albert Einstein College of Medicine
出版物と役立つリンク
一般刊行物
- Hayes BT, Favaro J, Davis CS, Gonsalves GS, Beletsky L, Vlahov D, Heimer R, Fox AD. Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. J Urban Health. 2021 Aug;98(4):532-537. doi: 10.1007/s11524-021-00534-1. Epub 2021 Mar 12. No abstract available.
- Hayes BT, Favaro J, Coello D, Behrends CN, Jakubowski A, Fox AD. Participants of a mail delivery syringe services program are underserved by other safe sources for sterile injection supplies. Int J Drug Policy. 2022 Jan;99:103474. doi: 10.1016/j.drugpo.2021.103474. Epub 2021 Oct 5.
- D'Angelo AB, Morrison CA, Lopez-Rios J, MacCrate CJ, Pantalone DW, Stief M, Grov C. Experiences Receiving HIV-Positive Results by Phone: Acceptability and Implications for Clinical and Behavioral Research. AIDS Behav. 2021 Mar;25(3):709-720. doi: 10.1007/s10461-020-03027-5.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2022-14407
- K24DA057873 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。